Walvax subsidiary secures credit, revises bylaws, boosts equity stake

Yuxi Walvax Biotechnology Co., Ltd. secured Rmb600 million in credit from China Merchants Bank and Everbright Bank for R&D, production, sales, and operational expenses, with a one-year term and no collateral requirement. This move is part of broader operational and governance updates for Walvax Biotechnology.

Walvax Biotechnology will acquire a 2.4793% stake from Tianjin Lanwo Investment Partnership for Rmb35,949,850 and an 11.3043% stake from Huixiang Yuetai Investment Partnership for Rmb163,912,350. These acquisitions aim to strengthen control and enhance profitability.

Furthermore, Walvax Biotechnology plans to offer foreign exchange hedging facilities of up to $50 million or equivalent to mitigate currency risks. The company also confirmed its engagement of Daxin Certified Public Accountants LLP for its 2025 financial and internal control audits and approved a Rmb10 million donation to the Yunnan Normal University Education Foundation for scientific forums and awards. Several corporate bylaws, including the Articles of Association and rules for shareholders' and board meetings, are being revised to align with new regulations and optimize governance.